Clinical data | |
---|---|
Trade names | Ibrance, others |
Other names | PD-0332991 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a615013 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 46% |
Protein binding | 85% |
Metabolism | Liver (CYP3A, SULT2A1, glucuronidation) |
Elimination half-life | 29 (±5) hours |
Excretion | 74% feces, 18% urine |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.238.221 |
Chemical and physical data | |
Formula | C24H29N7O2 |
Molar mass | 447.543 g·mol−1 |
3D model (JSmol) | |
| |
|
Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.[5][6] Palbociclib was the first CDK4/6 inhibitor to be approved as a cancer therapy.[7]
Finn2009
was invoked but never defined (see the help page).pmid24369047
was invoked but never defined (see the help page).